Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026)
Aura Biosciences (AURA) posted Cash from Financing Activities of $300000.0 for Q1 2026, down 89.16% on a QoQ basis from $2.8 million in Q4 2025, and up 212.5% year-over-year from $96000.0 in Q1 2025.
Aura Biosciences (AURA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Aura Biosciences' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- Quarterly Cash from Financing Activities rose 212.5% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.4 million (up 5279.62% YoY) and the FY2025 annual result came in at $77.2 million, up 4737.3% from the prior year.
- Cash from Financing Activities was $300000.0 for Q1 2026 at Aura Biosciences, down from $2.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $95.2 million in Q4 2022 and bottomed at $17000.0 in Q1 2022.
- A 5-year average of $16.0 million and a median of $543000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.98% — and 2025, when it surged 84151.81%.
- Aura Biosciences' Cash from Financing Activities stood at $95.2 million in 2022, then retreated by 2.33% to $93.0 million in 2023, then slumped by 99.42% to $543000.0 in 2024, then surged by 409.58% to $2.8 million in 2025, then sank by 89.16% to $300000.0 in 2026.
- Business Quant data shows AURA's Cash from Financing Activities at $300000.0 in Q1 2026, $2.8 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Aura Biosciences | 485.62 Mn | 400.83 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 2.77 Mn |
| Dec 31, 2025 | 2.77 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 69.93 Mn |
| Jun 30, 2025 | 69.93 Mn |
| Mar 31, 2025 | 96,000.00 |
| Mar 31, 2025 | 96,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Dec 31, 2024 | 543,000.00 |
| Sep 30, 2024 | 716,000.00 |
| Sep 30, 2024 | 716,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 83,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Mar 31, 2024 | 253,000.00 |
| Dec 31, 2023 | 92.99 Mn |
| Dec 31, 2023 | 92.99 Mn |